Navigation Links
TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Date:10/13/2009

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the number of multidrug-resistant (MDR) bacterial pathogens that have emerged and spread in recent years has dramatically reduced the utility of the current arsenal of antibiotics. Two such MDR pathogens in particular have been recognized as major threats to global public health, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). TAXIS is in the process of identifying and validating lead drug candidates that target MRSA and VRE with efficacies that are superior to current standards of therapeutic care.

"The compounds under investigation have great potential to treat a broad-spectrum of emerging, drug-resistant pathogens that represent large and growing public health and biodefense threats", said Gregory Mario, TAXIS' Chief Executive Officer. "We are excited to develop these further and move them closer to the clinic." The novel antimicrobial technology was discovered at the universities by Professors Daniel S. Pilch, Ph.D. (Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School) and Edmond J. LaVoie, Ph.D. (Department of Medicinal Chemistry, Rutgers University-Ernest Mario School of Pharmacy).


'/>"/>

Contact: Gregory G. Mario
GMario@TAXISPharma.com
609-240-8463
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
2. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
3. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
4. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Bacteria from sponges make new pharmaceuticals
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Spectra Automation, a trusted ... biotech and power generation industries, announced today ... Manager, an easy-to-use and cost-effective data collection, ... development laboratories. Most upstream ... analyzer systems. Accessing and consolidating data from ...
(Date:9/29/2014)... called Clostridium ramosum , coupled with a high-fat diet, ... this week in mBio , the online open-access journal ... team from the German Institute of Human Nutrition Potsdam-Rehbruecke in ... C. ramosum gained weight when fed a high-fat diet. ... less obese even when consuming a high-fat diet, and mice ...
(Date:9/29/2014)... story from 2009, "human activities in this area of the ... oil is increasingly grown for use as a cooking oil ... It has become the most widely produced edible oil in ... surpass that of soybean oil. , The environmental effects of ... to grow the crop, and the preferred method is fire. ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Gut bacteria promote obesity in mice 2
... 2013 UT Southwestern Medical Center researchers report that ... to inflammatory disease, indicating that the production of a ... clock. The study published in the Nov. 8 ... pathway by which the body,s circadian clock controls the ...
... Science Foundation (NSF), in cooperation with interagency and ... awards under a program that supports multi- and ... and sustainability of the natural and living environment, ... the Arctic. Six projects have been ...
... URBANA, Ill. Despite a 12-year action plan calling for ... progress has been made, and there is no evidence that ... University of Illinois researchers have identified some of the biophysical ... "We are suggesting that a partnership of researchers work ...
Cached Biology News:UT Southwestern researchers identify how body clock affects inflammation 2UT Southwestern researchers identify how body clock affects inflammation 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 2NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 3NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 4NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 5NSF, with interagency and international partners, makes first round of grants to understand Arctic sustainability 6Researchers suggest plan to address hypoxia in Gulf of Mexico 2Researchers suggest plan to address hypoxia in Gulf of Mexico 3
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview ... a session that he will lead on “Stem Cells” at ... 17-18, 2015 in London. In the interview posted ... to respond to several questions on the current state of ... cell toxicity, and future trends in the use of stem ...
(Date:9/29/2014)... CA (PRWEB) September 30, 2014 ... million burn injuries require medical attention. In the ... brings serious complications to battlefield medical care. More ... Iraq and Afghanistan. Burn wounds heal slowly, remain ... can be excessive, physically debilitating and functionally damaging. ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... Calif., Jan. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of peripheral vascular disease,announced today that ... quarter ended December 31, 2007, after the close of ... regular quarterly teleconference at 2:00 p.m. PT,/ 5:00 p.m. ...
... Two Development Milestones in its Ofatumumab ... Collaboration With GlaxoSmithKline., COPENHAGEN, January 21 ... second and third development milestones,for ofatumumab (HuMax-CD20(R)) under the terms ... of the collaboration of DKK 87.2 million,was triggered by treatment ...
... company insiders knowingly misrepresented the ... ... Sobol Shapiro filed a,proposed class-action lawsuit on behalf of CellCyte ... the company and chief executive officer Gary A.,Reys, background, causing ...
Cached Biology Technology:VNUS Medical Technologies to Report Fourth-Quarter 2007 Results and Webcast Teleconference on February 7 2Genmab Reaches Milestones in Ofatumumab Collaboration 2Genmab Reaches Milestones in Ofatumumab Collaboration 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3